Literature DB >> 16963232

Mechanisms of daptomycin resistance in Staphylococcus aureus.

Glenn W Kaatz1, Tammy S Lundstrom, Susan M Seo.   

Abstract

Daptomycin resistance in Staphylococcus aureus emerged during therapy of tricuspid endocarditis. Susceptibility to daptomycin of the parent strain (SA-675), other daptomycin-susceptible strains and the non-susceptible mutant (SA-684) was heterogeneous; however, subpopulations growing at concentrations above the minimum inhibitory concentration (MIC) were not stably resistant. Stable resistance was produced only by serial passage on daptomycin-containing media. Daptomycin dissipated the membrane potential of SA-675 but not SA-684, which also lost an 81 kDa membrane protein. Whole cells and membranes of SA-684 bound a reduced amount of daptomycin. Reduced drug binding in SA-684 correlates with daptomycin resistance, possibly as a result of the loss of a membrane protein 'chaperone' with which daptomycin interacts. Heterogeneity of daptomycin MICs in susceptible strains may be an important factor in the development of stable, clinically relevant resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963232     DOI: 10.1016/j.ijantimicag.2006.05.030

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  36 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

Authors:  Tatiana Bogdanovich; Catherine Clark; Klaudia Kosowska-Shick; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

3.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

4.  In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  Nagendra N Mishra; James McKinnell; Michael R Yeaman; Aileen Rubio; Cynthia C Nast; Liang Chen; Barry N Kreiswirth; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  Antibacterial photosensitization through activation of coproporphyrinogen oxidase.

Authors:  Matthew C Surdel; Dennis J Horvath; Lisa J Lojek; Audra R Fullen; Jocelyn Simpson; Brendan F Dutter; Kenneth J Salleng; Jeremy B Ford; J Logan Jenkins; Raju Nagarajan; Pedro L Teixeira; Matthew Albertolle; Ivelin S Georgiev; E Duco Jansen; Gary A Sulikowski; D Borden Lacy; Harry A Dailey; Eric P Skaar
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

6.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

7.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.

Authors:  Ilana Lopes Baratella da Cunha Camargo; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

9.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

10.  Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Glenn A Pankuch; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.